STAT Plus: Crash and burn: The four biggest biopharma failures of 2019
In biotech, companies fail for a lot of reasons.
The science might not quite work, the drug might be too difficult to sell or investors might run out of patience — or questionable practices might wind up undermining the whole endeavor.
Continue to STAT Plus to read the full story…
Read Original Article: STAT Plus: Crash and burn: The four biggest biopharma failures of 2019 »
